Table 2.
Motor outcome change scores at 12 months.
| n | Baseline | 12 Months | Change Score | p-Value | |
|---|---|---|---|---|---|
| MDS-UPDRS III (“on”) | |||||
| LA | 20 | 20.7 ± 10.5 | 21.8 ± 13.6 | 1.07 ± 15.2 | 0.67 |
| PSA | 43 | 22.7 ± 11.8 | 24.6 ± 13.2 | 1.85 ± 13.4 | |
| MDS-UPDRS II (“on”) | |||||
| LA | 14 | 9.4 ± 5.3 | 10.5 ± 4.9 | 1.67 ± 5.1 | 0.87 |
| PSA | 28 | 9.5 ± 4.9 | 11.8 ± 6.4 | 2.23 ± 5.6 | |
| LEDD | |||||
| LA | 22 | 1451 ± 788 | 829 ± 712 | −622 ± 560 | 0.59 |
| PSA | 48 | 1284 ± 619 | 626 ± 376 | −674 ± 559 |
p-value for group difference in change score from multivariate linear regression models; all models are adjusted for age, sex, and disease duration. The MDS-UPDRS III model was additionally adjusted for UPDRS-III at baseline “off” and LEDD at 12 months, and the MDS-UPDRS II model for UPDRS-II at baseline “off”. MDS-UPDRS: Movement Disorders Society Unified Parkinson’s Disease Rating Scale, LA: local anesthesia, LEDD: Levodopa equivalent daily dosage, PSA: Procedural sedation and/or analgesia.